T. Cosgriff

发表

Differential susceptibility of rhesus monkeys to high doses of endotoxin

D. Veloso, S. Denny, T. Cosgriff, 1995 .

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

Tae Min Kim, Ray Page, R. Motzer, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanisms of disease in hemorrhagic fever with renal syndrome.

T. Cosgriff, R. Lewis, 1991, Kidney international. Supplement.

A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.

T. Cosgriff, M. Min, T. Chidiac, 2011, Clinical breast cancer.

Efficacy and Safety Results From a Phase II, Placebo‐Controlled Study of Onartuzumab Plus First‐Line Platinum‐Doublet Chemotherapy for Advanced Squamous Cell Non–Small‐Cell Lung Cancer

R. Govindan, F. Hirsch, D. Gandara, 2017, Clinical lung cancer.

Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea☆

T. Cosgriff, J. Huggins, J. Rusnak, 2008, Antiviral Research.

Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome.

J. Leduc, T. Cosgriff, J. Huggins, 1991, The Journal of infectious diseases.

Mechanisms of disease in Hantavirus infection: pathophysiology of hemorrhagic fever with renal syndrome.

T. Cosgriff, 1991, Reviews of infectious diseases.

The reemergence of dengue in China.

T. Cosgriff, W. Fan, S. R. Yu, 1989, Reviews of infectious diseases.

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

R. Motzer, K. Pittman, C. Barrios, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Hemorrhagic fever virus-induced changes in hemostasis and vascular biology

J. P. Chen, T. Cosgriff, James P. Chen, 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Hematological and bone marrow effects of ribavirin in rhesus monkeys.

T. Cosgriff, M. Kastello, P. G. Canonico, 1984, Toxicology and applied pharmacology.

Viruses and hemostasis.

T. Cosgriff, Thomas M. Cosgriff, T. M. Cosgriff, 1989, Reviews of infectious diseases.

Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis.

T. Cosgriff, B. Martin, 1981, Arthritis and rheumatism.

Hemostatic derangement produced by Rift Valley fever virus in rhesus monkeys.

C. Peters, T. Cosgriff, J. Morrill, 1989, Reviews of infectious diseases.

Familial Antithrombin III Deficiency: Its Natural History, Genetics, Diagnosis and Treatment

M. Skolnick, D. Bishop, T. Cosgriff, 1983, Medicine.

Cetuximab + FOLFOX6 as first line therapy for metastatic colorectal cancer (An International Oncology Network study, I-03-002).

S. Dakhil, T. Cosgriff, R. Boccia, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum.

S. Hoffman, R. Carter, T. Cosgriff, 1986, The American journal of tropical medicine and hygiene.

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

J. Hainsworth, T. Cosgriff, A. Cohn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS).

T. Cosgriff, R. Lyons, I. Fernando, 2007 .

Sideroblastic anemia as a preleukemic event in patients treated for Hodgkin's disease.

H. Eyre, T. Cosgriff, M. Kitahara, 1980, Annals of internal medicine.

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

R. Motzer, K. Pittman, C. Barrios, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Hodgkin disease as the terminal malignancy in Richter syndrome.

T. Cosgriff, D. McCloskey, 1981, Medical and pediatric oncology.

Replication of hemorrhagic fever viruses in monocytic cells.

P. Jahrling, T. Cosgriff, J. Morrill, 1989, Reviews of infectious diseases.

Immune serum increases arenavirus replication in monocytes.

P. Jahrling, T. Cosgriff, R. Lewis, 1988, The Journal of general virology.

Platelet dysfunction contributes to the haemostatic defect in haemorrhagic fever with renal syndrome.

T. Cosgriff, H. W. Lee, R. Lewis, 1991, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Mefloquine failure in a case of falciparum malaria induced with a multidrug-resistant isolate in a non-immune subject.

T. Cosgriff, C. Canfield, G. Willet, 1985, The American journal of tropical medicine and hygiene.

Cetuximab + FOLFOX 6 as first line therapy for metastatic colorectal cancer

S. Dakhil, T. Cosgriff, R. Boccia, 2005 .

Studies of the coagulation system in arenaviral hemorrhagic fever: experimental infection of strain 13 guinea pigs with Pichinde virus.

J. P. Chen, P. Jahrling, T. Cosgriff, 1987, The American journal of tropical medicine and hygiene.

Case Report Long-Term Survival in Wiskott-Aldrich Syndrome: Case Report and Literature Review

T. Cosgriff, D. S. Cheng, M. Kitahara, 1981 .

Differentiation of a human monocytic cell line associated with increased production of Rift Valley fever virus by infected cells

C. Peters, T. Cosgriff, J. Morrill, 1987, Journal of medical virology.

Hemorrhage in hemorrhagic fever with renal syndrome in China.

T. Cosgriff, M. Guang, G. Liu, 1989, Reviews of infectious diseases.

Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha.

C. Peters, T. Cosgriff, J. Morrill, 1989, Reviews of infectious diseases.

Morphological alterations in blood and bone marrow of ribavirin-treated monkeys.

T. Cosgriff, M. Kastello, J. D. White, 1984, Acta haematologica.

Digital vasospasm and infarction associated with hepatitis B antigenemia.

T. Cosgriff, W. Arnold, 1976, JAMA.

Successful treatment of severe refractory idiopathic thrombocytopenic purpura with liposomal doxorubicin

T. Cosgriff, W. Stein, M. Black, 1998, American journal of hematology.

Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.

T. Cosgriff, R. Lyons, J. Backstrom, 2006 .

Safety and immunogenicity of a Plasmodium vivax sporozoite vaccine.

T. Cosgriff, I. Schneider, J. Chulay, 1990, The American journal of tropical medicine and hygiene.

False assignment of familial antithrombin III deficiency with the von Kaulla assay.

T. Cosgriff, K. Carlson, B. Martin, 1983, American journal of clinical pathology.

Structure, Kinetics, and Function of Human and Rhesus Plasma Prekallikreins Are Similar

Joshua R. Smith, D. Veloso, T. Cosgriff, 1992, Thrombosis and Haemostasis.

The hemostatic derangement produced by T-2 toxin in cynomolgus monkeys.

T. Cosgriff, R. Wannemacher, R. Dinterman, 1986, Toxicology and applied pharmacology.

The hemostatic derangement produced by T-2 toxin in guinea pigs.

T. Cosgriff, R. Wannemacher, R. Dinterman, 1984, Toxicology and applied pharmacology.

Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response

C. Peters, T. Cosgriff, J. Morrill, 2005, Archives of Virology.

Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04-012)

T. Cosgriff, M. Min, T. Chidiac, 2008 .

Efficacy and Safety of Onartuzumab in Combination With First‐Line Bevacizumab‐ or Pemetrexed‐Based Chemotherapy Regimens in Advanced Non‐Squamous Non–Small‐Cell Lung Cancer

H. Wakelee, S. Novello, F. D. De Braud, 2017, Clinical lung cancer.

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

J. Hainsworth, K. Pierce, C. Langer, 2007, Cancer Chemotherapy and Pharmacology.

Primary T-cell lymphoma of muscle in a patient infected with human immunodeficiency virus.

T. Cosgriff, R. Byrne, V. Reddy, 1993, American Journal of Medicine.

Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

R. Motzer, K. Pittman, C. Barrios, 2015 .

Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669).

T. Cosgriff, C. Canfield, R. Desjardins, 1982, The American journal of tropical medicine and hygiene.

Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer.

T. Cosgriff, T. Reid, F. Valone, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Antithrombin III Content of Cryoprecipitate Prepared from Blood Collected with and without Heparin 1

T. Cosgriff, L. A. Hodgson, J. V. West, 1983, Vox sanguinis.

Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).

R. Motzer, K. Pittman, C. Barrios, 2013 .

Rhesus differential susceptibility to endotoxin is not associated with activation of plasma prekallikrein.

D. Veloso, T. Cosgriff, J. I. Smith, 1999, Immunopharmacology.

Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).

R. Motzer, D. Ye, B. Alekseev, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.

S. Dakhil, T. Cosgriff, R. Boccia, 2010, Clinical colorectal cancer.

Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer.

C. Redfern, J. Carmichael, D. Cunningham, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Hemorrhagic fever with renal syndrome: four decades of research.

T. Cosgriff, T M Cosgriff, 1989, Annals of internal medicine.

Doxorubicin and ventricular arrhythmia.

T. Cosgriff, 1980, Annals of internal medicine.

Changes in populations of immune effector cells during the course of haemorrhagic fever with renal syndrome.

T. Cosgriff, H. W. Lee, R. Lewis, 1991, Transactions of the Royal Society of Tropical Medicine and Hygiene.

ATCT-33RESULTS FROM EARLY CLINICAL TRIALS FOR 4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE (DM-CHOC-PEN).

Jay-Jiguang Zhu, P. Friedlander, M. Ware, 2015 .

RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC).

R. Motzer, S. Segal, Liping Xie, 2015 .

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

R. Motzer, K. Pittman, C. Barrios, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.